Luzhu Bio-B (02480) published LZ901 phase III clinical trial results in Nature Communications

Zhitongcaijing · 2d ago

Zhitong Finance App News, Luzhu Bio-B (02480) announced that the results of phase III clinical trials of the Group's core product LZ901 in China were published in Nature Communications on August 7, 2026.

The phase III clinical trial of LZ901 in China is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the protective efficacy and safety of LZ901 in preventing shingles in adults aged 40 and above. A total of 26,039 participants were enrolled in the study. A total of 25,577 participants received two doses of LZ901 or placebo at intervals of 30 days.